Get the Stockscreener App
3.07
5.25%
-0.17
Taysha Gene Therapies Inc stock is traded at $3.07, with a volume of 4.42M.
It is down -5.25% in the last 24 hours and up +5.50% over the past month.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
See More
Previous Close:
$3.24
Open:
$3.24
24h Volume:
4.42M
Relative Volume:
1.43
Market Cap:
$837.48M
Revenue:
$8.10M
Net Income/Loss:
$-92.72M
P/E Ratio:
-9.0294
EPS:
-0.34
Net Cash Flow:
$-82.52M
1W Performance:
-8.63%
1M Performance:
+5.50%
6M Performance:
+76.44%
1Y Performance:
+40.18%
1-Day Range:
$3.04
$3.27
1-Week Range:
$3.04
$3.40
52-Week Range:
$1.05
$3.40
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Name
Taysha Gene Therapies Inc
Sector
Industry
Phone
(214) 612-0000
Address
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
3.07 | 886.58M | 8.10M | -92.72M | -82.52M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | BofA Securities | Buy |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Apr-09-24 | Initiated | Piper Sandler | Overweight |
| Feb-01-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-27-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-22 | Downgrade | Goldman | Buy → Neutral |
| Mar-09-22 | Initiated | Robert W. Baird | Outperform |
| Mar-01-22 | Initiated | Wells Fargo | Overweight |
| Feb-18-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | Guggenheim | Buy |
| Jul-16-21 | Initiated | Needham | Buy |
| Jun-24-21 | Initiated | Truist | Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Jun-09-21 | Initiated | Wedbush | Outperform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| May-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-21 | Resumed | Jefferies | Buy |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Jan-05-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Chardan Capital Markets | Buy |
| Oct-19-20 | Initiated | Goldman | Buy |
| Oct-19-20 | Initiated | Jefferies | Buy |
| Oct-19-20 | Initiated | Morgan Stanley | Overweight |
View All
Taysha Gene Therapies Inc Stock (TSHA) Latest News
Siren L.L.C. Sells 87,738 Shares of Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Octagon Capital Advisors LP Has $14.87 Million Holdings in Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Screener Results Flag Taysha Gene Therapies Inc. as OversoldTrade Risk Summary & Verified Entry Point Signals - beatles.ru
Nuveen LLC Acquires New Holdings in Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Palo Alto Investors LP Purchases 608,200 Shares of Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Published on: 2025-09-06 13:01:15 - Newser
Real time breakdown of Taysha Gene Therapies Inc. stock performance2025 Analyst Calls & Momentum Based Trading Signals - Newser
Is Taysha Gene Therapies Inc. benefiting from interest rate changesJuly 2025 Chart Watch & Fast Momentum Entry Tips - خودرو بانک
Is Taysha Gene Therapies Inc. subject to activist investor interestWeekly Profit Analysis & Safe Capital Growth Tips - خودرو بانک
Taysha Gene Therapies Inc. stock prediction for this weekJobs Report & Verified Short-Term Plans - Newser
Can Taysha Gene Therapies Inc. outperform under higher oil prices2025 Market Outlook & Daily Growth Stock Investment Tips - خودرو بانک
Published on: 2025-09-05 16:05:08 - Newser
What institutional flow reveals about Taysha Gene Therapies Inc.2025 Winners & Losers & Daily Profit Focused Screening - Newser
Is Taysha Gene Therapies Inc. stock entering bullish territoryQuarterly Market Review & Comprehensive Market Scan Reports - Newser
Trapped Investors in Taysha Gene Therapies Inc. Await Breakout SignalJuly 2025 Momentum & Consistent Growth Equity Picks - beatles.ru
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule 5635(c)(4) - MarketScreener
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Li - GuruFocus
Taysha Gene Therapies (TSHA) Awards Stock Options to New Employe - GuruFocus
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
225,000 Shares: Gene Therapy Biotech Taysha Grants Stock Options to Expand CNS Research Team - Stock Titan
Real time social sentiment graph for Taysha Gene Therapies Inc.Quarterly Growth Report & AI Forecast for Swing Trade Picks - Newser
How high can Taysha Gene Therapies Inc. stock goJuly 2025 Setups & High Conviction Investment Ideas - Newser
What earnings revisions data tells us about Taysha Gene Therapies Inc.Trade Risk Report & Fast Exit/Entry Strategy Plans - Newser
Taysha Gene Therapies Inc. stock retracement – recovery analysisTreasury Yields & AI Powered Trade Plan Recommendations - Newser
Taysha Gene Therapies Inc. stock volume spike explainedMarket Growth Summary & Real-Time Volume Analysis - Newser
Taysha Gene (TSHA.O) Surges 10.17% on KDJ Golden Cross and Weak Peer Performance - AInvest
Breakout Move: Can Taysha Gene Therapies Inc. sustain earnings growth2025 Support & Resistance & Technical Pattern Recognition Alerts - خودرو بانک
Is Taysha Gene Therapies Inc. a candidate for recovery playMarket Volume Report & Advanced Swing Trade Entry Plans - Newser
How to build a custom watchlist for Taysha Gene Therapies Inc.July 2025 Outlook & Reliable Intraday Trade Plans - Newser
What are Taysha Gene Therapies Inc.’s earnings expectations2025 Fundamental Recap & Reliable Entry Point Trade Alerts - خودرو بانک
Will Taysha Gene Therapies Inc. benefit from sector rotation2025 Pullback Review & Smart Investment Allocation Insights - خودرو بانک
Gains Recap: Can Taysha Gene Therapies Inc. deliver alpha2025 Retail Activity & Stock Portfolio Risk Management - خودرو بانک
How liquid is Taysha Gene Therapies Inc. stockWeekly Earnings Recap & Weekly Top Stock Performers List - خودرو بانک
What’s next for Taysha Gene Therapies Inc. stock priceJuly 2025 WrapUp & Expert Curated Trade Setup Alerts - Newser
Highs Report: Is Taysha Gene Therapies Inc. benefiting from interest rate changesJuly 2025 News Drivers & AI Enhanced Trade Execution Alerts - خودرو بانک
Published on: 2025-09-03 02:33:41 - Newser
Using data filters to optimize entry into Taysha Gene Therapies Inc.Dollar Strength & Reliable Breakout Forecasts - Newser
Taysha Gene Therapies Inc.’s volatility index tracking explainedJuly 2025 Snapshot & Fast Moving Market Watchlists - Newser
Will Taysha Gene Therapies Inc. stock go up soonJuly 2025 WrapUp & Advanced Swing Trade Entry Plans - Newser
Using portfolio simulators with Taysha Gene Therapies Inc. includedMarket Rally & Low Drawdown Investment Ideas - Newser
Is Taysha Gene Therapies Inc. showing signs of accumulationJuly 2025 Selloffs & Detailed Earnings Play Strategies - Newser
Is Taysha Gene Therapies Inc. stock reversal real or fakeJuly 2025 Reactions & Short-Term High Return Strategies - Newser
Taysha Gene Therapies Inc Stock (TSHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Taysha Gene Therapies Inc Stock (TSHA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nagendran Sukumar | President and Head of R&D |
Sep 10 '25 |
Sale |
3.23 |
200,000 |
646,000 |
1,006,439 |
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):